**Avastin Injection Procedure Note**

AVASTIN EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE:Avastin Injection Procedure Note

ANESTHESIA: Topical Proparacaine, 2% Lidocaine without Epinephrine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, a paper ABN was signed and a copy provided to the patient. Drops of Proparacaine were given in treated eye. Subconjunctival injection of 2% Lidocaine without epinephrine was placed in inferior-temporal or superotemporal conjunctiva at limbus. The eyelids and conjunctiva were prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.05cc of Avastin (1.25mg) was then given. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Avastin Injection without Numbing Injection Procedure Note**

AVASTIN EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE:Avastin Injection without Numbing Injection Procedure Note

ANESTHESIA: Alcaine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, a paper ABN was signed and a copy provided to the patient. A drop of Alcaine was given in treated eye. The eyelids and conjunctiva were prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.05cc of Avastin (1.25mg) was then given. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. Next a drop of ocular antibiotic and glaucoma drop were then given. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Lucentis 0.5 Injection Procedure Note**

LUCENTIS 0.5 EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE:Lucentis 0.5 Injection Procedure Note

ANESTHESIA: Topical Proparacaine, 2% Lidocaine without Epinephrine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, an ABN was signed and a copy provided to the patient. Drops of Proparacaine were given in treated eye. Subconjunctival injection of 2% Lidocaine without epinephrine was placed in inferior-temporal or superotemporal conjunctiva at limbus. The eyelids and conjunctiva were prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.05cc of Lucentis 0.5 mg was then given. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. The patient tolerated the procedure well. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Lucentis 0.5 Injection without Numbing Injection Procedure Note**

LUCENTIS 0.5 EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE:Lucentis 0.5 Injection without Numbing Injection Procedure Note

ANESTHESIA: Alcaine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, an ABN was signed and a copy provided to the patient. A drop of Alcaine was given in treated eye. The eyelid and conjunctiva was prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.05cc of Lucentis 0.5 mg was then given. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. Next a drop of ocular antibiotic and a glaucoma drop were then given. The patient tolerated the procedure well. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Lucentis .3 Injection Procedure Note**

LUCENTIS 0.3 EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE: Lucentis .3 Injection Procedure Note

ANESTHESIA: Topical Proparacaine,2% Lidocaine without Epinephrine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, a paper ABN was signed and a copy provided to the patient. Drops of Proparacaine were given in both eyes. The eyelid and conjunctiva was prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.05cc Lucentis 0.3mg was then given.When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. Next a drop of ocular antibiotic and a glaucoma drop were then given. The patient tolerated the procedure well. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Lucentis .3 Injection without Numbing Injection Procedure Note**

LUCENTIS 0.3 EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE:Lucentis .3 Injection without Numbing Injection Procedure Note

ANESTHESIA: Alcaine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, an ABN was signed and a copy provided to the patient. A drop of Alcaine was given in treated eye. The eyelid and conjunctiva was prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.05cc of Lucentis 0.5 mg was then given. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. Next a drop of ocular antibiotic and a glaucoma drop were then given. The patient tolerated the procedure well. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Eylea Injection Procedure Note**

EYLEA EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE: Eylea Injection Procedure Note

ANESTHESIA: Topical Proparacaine, 2% Lidocaine without Epinephrine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, an ABN was signed and a copy provided to the patient. Drops of Proparacaine were given in treated eye. Subconjunctival injection of 2% Lidocaine without epinephrine was placed in inferior-temporal or superotemporal conjunctiva at limbus. The eyelids and conjunctiva were prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.05cc of EYLEA (2mg) was then given at marked area. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Eylea Injection without Numbing Injection Procedure Note**

EYLEA EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE: Eylea Injection without Numbing Injection Procedure Note

ANESTHESIA: Topical Proparacaine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, an ABN was signed and a copy provided to the patient. Drops of Proparacaine were given in treated eye. The eyelids and conjunctiva were prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.05cc of EYLEA (2mg) was then given at marked area. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. Next a drop of ocular antibiotic and glaucoma drop were then given. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Ozurdex Injection Procedure Note**

OZURDEX EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE: Ozurdex Injection Procedure Note

ANESTHESIA: Topical Proparacaine, 2% Lidocaine without Epinephrine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, an ABN was signed and a copy provided to the patient. Drops of Proparacaine were given in treated eye. Subconjunctival injection of 2% Lidocaine without epinephrine was placed in inferior-temporal or superotemporal conjunctiva at limbus. The eyelids and conjunctiva were prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. Ozurdex 0.7 mg was then injected. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Ozurdex Injection without Numbing Injection Procedure Note**

OZURDEX EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE:Ozurdex Injection without Numbing Injection Procedure Note

ANESTHESIA: Topical Proparacaine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, an ABN was signed and a copy provided to the patient. Drops of Proparacaine were given in treated eye. The eyelids and conjunctiva were prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. Ozurdex 0.7 mg was then injected. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. Next a drop of ocular antibiotic and glaucoma drop were then given. Pt was given an antibiotic drop RX for 1 drop QID for 7 days. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**JETREA Injection Procedure Note**

JETREA EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE: JETREA Injection Procedure Note

ANESTHESIA: Topical Proparacaine, 2% Lidocaine without Epinephrine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, a paper ABN was signed and a copy provided to the patient. Drops of Proparacaine were given in both eyes. Subconjunctival injection of 2% Lidocaine without Epinephrine was placed in inferior-temporal or superotemporal conjunctiva at limbus. The eyelid and conjunctiva was prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.125 of JETREA (2.5mg/mL) was then given. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. Next a drop of ocular antibiotic and a glaucoma drop were then given. The patient tolerated the procedure well. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**JETREA Injection without Numbing Injection Procedure Note**

JETREA EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE:JETREA Injection without Numbing Injection Procedure Note ANESTHESIA: Alcaine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, a paper ABN was signed and a copy provided to the patient. A drop of Alcaine was given in both eyes. The eyelid and conjunctiva was prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.125 of JETREA (2.5mg/mL) was then given.When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better.Next a drop of ocular antibiotic and a glaucoma drop were then given. The patient tolerated the procedure well. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Dexamethasone Injection Procedure Note**

DEXAMETHASONE EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE:Dexamethasone Injection Procedure Note

ANESTHESIA: Topical Proparacaine, 2% Lidocaine without Epinephrine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, an ABN was signed and a copy provided to the patient. Drops of Proparacaine were given in treated eye. Subconjunctival injection of 2% Lidocaine without epinephrine was placed in inferior-temporal or superotemporal conjunctiva at limbus. The eyelids and conjunctiva were prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. Dexamethasone Sodium Phosphate 0.1cc/400mcg was then injected. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. Next a drop of ocular antibiotic and glaucoma drop were then given. Pt was given an antibiotic drop RX for 1 drop QID for 7 days. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Macugen Injection Procedure Note**

MACUGEN EYE: **XXX** DIAGNOSIS: **XXX** ADMINISTERED MEDICATION: AVASTIN; MEDICATION INVENTORY NUMBER: **XXX**

MEDICATION LOT NUMBER: **XXX** MEDICATION DOSAGE: 1.25mg/0.05ml; OP NOTE:Macugen Injection Procedure Note

ANESTHESIA: Topical Proparacaine, 2% Lidocaine without epinephrine

COMPLICATIONS: None. The patient tolerated the procedure well.

INDICATIONS: See medical record

DESCRIPTION OF PROCEDURE: After proper informed consent was obtained, a paper ABN was signed and a copy provided to the patient. Drops of Proparacaine were given in treated eye. Subconjunctival injection of 2% Lidocaine without epinephrine was placed in inferior-temporal or superotemporal conjunctiva at limbus. The eyelid and conjunctiva was prepped with a 5% povidone-iodine solution. Iodine was allowed to remain on the injection site for at least 30 seconds before the injection was given. An injection of 0.05cc of Macugen 2mg was then given. When necessary, IOP is checked using a Goldmann tonometer and appropriate measures are taken to lower IOP to improve disc perfusion. Disc perfusion intact based on post injection vision of hand motion or better. All residual medication in vial or prefilled syringe was discarded in the appropriate container.

POST OP & INSTRUCTIONS: The patient was given post-op instructions and asked to return again as per recommendation. The patient was discharged in good condition. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Epilation Procedure Note**

**EYE** EPILATION EYE: **XXX** LID LOCATION: **XXX** DIAGNOSIS: **XXX** REASON FOR PROCEDURE: **XXX**

OP NOTE: Epilation Procedure Note

ANESTHESIA: Topical Proparacaine

COMPLICATIONS: None.

INDICATIONS: The patient presented with trichiatic (inward turning) eyelashes, posing a risk of corneal abrasion or possible ulcer.

DESCRIPTION OF PROCEDURE: Following a discussion of risks, benefits, & alternatives, including no treatment, and having received the patient's agreement to proceed, trichiatic lashes were epilated with sterile jewelers without complication from the eyelids mentioned.

POST OP & INSTRUCTIONS: None. Patient can resume normal activities. DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Temporary (6 month dissolvable) Punctal Plug (Occlusion) Procedure Note**

**EYE** PUNCTAL PLUGS 6 Month Dissolvable EYE: **XXX** LID LOCATION: **XXX** DIAGNOSIS: **XXX** LOT#: **XXX** EXP: **XXX** REASON FOR PROCEDURE: **XXX**

OP NOTE: Temporary (6 month dissolvable) Punctal Plug (Occlusion) Procedure Note

ANESTHESIA: n/a

COMPLICATIONS: None.

INDICATIONS: The patient presented with a decreased tear film and a rapid tear break up time, characteristic of Dry Eye Syndrome (68761, 375.15) Risks, benefits, & alternatives, including no treatment, were discussed and the patient's agreement was received.

DESCRIPTION OF PROCEDURE: 6 month dissolvable punctual plugs were placed in the punctas stated above.

POST OP & INSTRUCTIONS: n/a DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Temporary (7 Days Collagen) Punctal Plug (Occlusion) Procedure Note**

**EYE** PUNCTAL PLUGS 7 Day Collagen EYE: **XXX** LID LOCATION: **XXX** DIAGNOSIS: **XXX** LOT#: **XXX** EXP: **XXX** REASON FOR PROCEDURE: **XXX**

OP NOTE: Temporary (7 Days Collagen) Punctal Plug (Occlusion) Procedure Note

ANESTHESIA: n/a

COMPLICATIONS: None.

INDICATIONS: The patient presented with a decreased tear film and a rapid tear break up time, characteristic of Dry Eye Syndrome (68761, 375.15) Risks, benefits, & alternatives, including no treatment, were discussed and the patient's agreement was received.

DESCRIPTION OF PROCEDURE: Temporary punctual plugs were placed in the punctas stated above.

POST OP & INSTRUCTIONS: n/a DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**Non-Dissolvable (Permanent) Punctal Plugs (Occlusion) Procedure Note**

**EYE** PUNCTAL PLUGS Permanent Non-Dissolvable EYE: **XXX** LID LOCATION: **XXX** DIAGNOSIS: **XXX** LOT#: **XXX** EXP: **XXX** REASON FOR PROCEDURE: **XXX**

OP NOTE: Non-Dissolvable (Permanent) Punctal Plugs (Occlusion) Procedure Note

ANESTHESIA: n/a

COMPLICATIONS: None.

INDICATIONS: The patient presented with a decreased tear film and a rapid tear break up time, characteristic of Dry Eye Syndrome (68761, 375.15) Risks, benefits, & alternatives, including no treatment, were discussed and the patient's agreement was received.

DESCRIPTION OF PROCEDURE: Non-dissolvable punctual plugs were placed in the punctas stated above.

POST OP & INSTRUCTIONS: n/a DOCTOR: Gary Ganiban MD;

-------------------------------------------------------------------------------

**FOCAL LASER:**

EYE | Focal Laser Photocoag (Argon) | Gary Ganiban, MD | LASER, Number of Spots XX, Power= 100mw, Duration= 0.2sec, Spot Size= 100microns

PROCEDURE DATE: XXXX

ACCOUNT#: XXXX

DOB: XXXX

PROCEDURE NAME: Focal Laser Photocoag (Argon)

ORIENTATION/MOOD/AFFECT: Alert & Oriented X 3

SEX: XXXX

PHYSICIAN: Gary Ganiban MD

ASSISTANT: XXXX

LOCATION: The Eye Institute XXXX Office

COMPLAINTS: XXXX

EYE TO BE TREATED: XXXX

PRE DIAGNOSIS: XXXX

POST DIAGNOSIS:

PROCEDURE DONE: XXXX

COMPLICATIONS ENCOUNTERED: NONE

DISCHARGE STATUS: To Home

FOLLOW UP INSTRUCTIONS: as in plan

TREATMENT: Number of Spots XX| Power= 100mw| Duration= 0.2sec| Spot Size= 100microns

ALLERGIES RECORDED: Latex

created by:Gary Ganiban, MD